CJC-1295 Research: Long-Acting GHRH-Analog Signaling

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone built around the GHRH(1-29) sequence with modifications intended to extend how long it persists. It's studied for the same upstream role as other GHRH compounds — prompting pituitary growth-hormone release — but with prolonged kinetics. Educational reference summary only; no human use is described.

Engineered for a longer half-life

The defining research feature of CJC-1295 is duration. A clinical-research report described prolonged stimulation of growth hormone and IGF-1 following administration, consistent with its extended-half-life design (Teichman et al., J Clin Endocrinol Metab, 2006). [1] That longer signaling window is the whole point of the modification.

Built on the GHRH(1-29) scaffold

CJC-1295 shares the GHRH(1-29) active core characterized in structure-activity research (Cervini et al., J Med Chem, 1998), [2] which is why it's studied alongside sermorelin and tesamorelin as part of the GHRH-analog family.

Analytical identification

Because of its research profile, CJC-1295 has also been characterized analytically — for example, methods to identify it in plasma — which is useful context for confirming material identity (Henninge et al., Drug Test Anal, 2010). [3]